(NASDAQ: SXTP) 60 Degrees Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.68%.
60 Degrees Pharmaceuticals's earnings in 2026 is -$8,063,060.On average, 4 Wall Street analysts forecast SXTP's earnings for 2026 to be -$8,571,417, with the lowest SXTP earnings forecast at -$8,287,405, and the highest SXTP earnings forecast at -$8,767,673. On average, 3 Wall Street analysts forecast SXTP's earnings for 2027 to be -$1,464,736, with the lowest SXTP earnings forecast at -$1,407,295, and the highest SXTP earnings forecast at -$1,507,816.
In 2028, SXTP is forecast to generate -$1,193,488 in earnings, with the lowest earnings forecast at -$1,146,685 and the highest earnings forecast at -$1,228,591.